Quadrature Capital Ltd Makes New Investment in Cardlytics, Inc. (NASDAQ:CDLX)

Quadrature Capital Ltd purchased a new position in Cardlytics, Inc. (NASDAQ:CDLXFree Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 19,652 shares of the company’s stock, valued at approximately $63,000.

Other hedge funds have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its position in shares of Cardlytics by 6.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 29,769 shares of the company’s stock valued at $432,000 after acquiring an additional 1,774 shares during the period. Canton Hathaway LLC increased its position in shares of Cardlytics by 95.7% in the second quarter. Canton Hathaway LLC now owns 4,500 shares of the company’s stock valued at $37,000 after acquiring an additional 2,200 shares during the period. Bank of New York Mellon Corp increased its position in shares of Cardlytics by 15.4% in the second quarter. Bank of New York Mellon Corp now owns 135,924 shares of the company’s stock valued at $1,116,000 after acquiring an additional 18,179 shares during the period. Ingalls & Snyder LLC increased its position in shares of Cardlytics by 106.0% in the second quarter. Ingalls & Snyder LLC now owns 32,464 shares of the company’s stock valued at $267,000 after acquiring an additional 16,708 shares during the period. Finally, Quest Partners LLC increased its position in shares of Cardlytics by 160.4% during the second quarter. Quest Partners LLC now owns 17,956 shares of the company’s stock valued at $147,000 after buying an additional 11,061 shares during the period. 68.10% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

CDLX has been the topic of several research analyst reports. Bank of America cut shares of Cardlytics from a “neutral” rating to an “underperform” rating and reduced their price target for the company from $4.00 to $3.50 in a research report on Thursday, August 15th. Needham & Company LLC reiterated a “hold” rating on shares of Cardlytics in a research report on Thursday, November 7th. Evercore ISI initiated coverage on shares of Cardlytics in a research report on Friday, October 11th. They set an “in-line” rating and a $4.00 price target on the stock. Northland Capmk cut shares of Cardlytics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 16th. Finally, Craig Hallum upgraded shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $6.92.

View Our Latest Research Report on Cardlytics

Cardlytics Price Performance

Shares of CDLX opened at $3.58 on Friday. The firm’s 50-day simple moving average is $3.89 and its two-hundred day simple moving average is $5.48. The stock has a market cap of $181.94 million, a PE ratio of -0.59 and a beta of 1.53. Cardlytics, Inc. has a fifty-two week low of $2.89 and a fifty-two week high of $20.52. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18.

Cardlytics (NASDAQ:CDLXGet Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.18. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 110.67%. The company had revenue of $67.06 million for the quarter, compared to the consensus estimate of $57.77 million. During the same quarter in the prior year, the firm earned ($0.26) earnings per share. The firm’s revenue for the quarter was down 15.1% compared to the same quarter last year. Analysts anticipate that Cardlytics, Inc. will post -1.52 earnings per share for the current fiscal year.

Insider Transactions at Cardlytics

In other Cardlytics news, CEO Amit Gupta sold 22,607 shares of the stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $3.85, for a total transaction of $87,036.95. Following the completion of the transaction, the chief executive officer now owns 178,519 shares in the company, valued at $687,298.15. This trade represents a 11.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Alexis Desieno sold 25,118 shares of the stock in a transaction on Friday, November 15th. The shares were sold at an average price of $3.43, for a total transaction of $86,154.74. Following the transaction, the chief financial officer now owns 116,481 shares of the company’s stock, valued at $399,529.83. This trade represents a 17.74 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 68,691 shares of company stock valued at $237,767 over the last three months. Corporate insiders own 4.40% of the company’s stock.

About Cardlytics

(Free Report)

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

Featured Stories

Want to see what other hedge funds are holding CDLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardlytics, Inc. (NASDAQ:CDLXFree Report).

Institutional Ownership by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.